Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Indivior Plc | INDV | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.00 | 0.13% | 745.50 | 16:35:28 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 735.50 | 734.00 | 755.00 | 745.50 | 744.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 04/3/2025 07:05 by waldron Indivior PLC Indivior PLC Files 2024 Annual Report on Form 10-K INDV +0.00%RNS Regulatory News - Today @ 07:00 Indivior PLC Files 2024 Annual Report on Form 10-K Richmond, VA, March 4, 2025 - Indivior PLC (NASDAQ/LSE: INDV) filed its Annual Report on Form 10-K for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission ("SEC") on March 3, 2025. The Annual Report on Form 10-K is now available at www.sec.gov and under the "Investors" section of the Company's website (www.indivior.com). |
Posted at 27/2/2025 07:28 by bulltradept Not for the departing CEO it's not.Hopefully, but what can a new guy do to help INDV? The last RNS warned specifically about other firms competing. |
Posted at 20/2/2025 07:46 by waldron Indivior Announces FY and Q4 2024 Financial Results20/02/2025 7:00am PR Newswire (US) Indivior (LSE:INDV) Intraday Stock Chart Thursday 20 February 2025 Click Here for more Indivior Charts. SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. Indivior (PRNewsfoto/Indivior The earnings release can be found at www.indivior.com/inv The investor presentation can be found at www.indivior.com/inv There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: hxxps://edge.media-s Participants may access the presentation telephonically by registering with the following link: [...] (Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on̷ Cision View original content to download multimedia: SOURCE Indivior PLC |
Posted at 07/2/2025 16:33 by waldron Indivior to Announce Q4 / FY 2024 Results and Host Webcast on February 20thSlough, UK, and Richmond, VA, February 4, 2025 - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will release its Q4 / FY 2024 results on February 20th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com. Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on February 20th. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. The webcast link: |
Posted at 07/11/2024 20:24 by imjustdandy Looks like hostile takeover - article just out Indivior PLC (NASDAQ:INDV) soared 13% amid some takeover speculation as well as a letter from one of its largest holders.Oaktree Capital Management, Indivior's second-largest holder with a 7.5% stake, wrote a letter on Wednesday to the company's board discussing its disappointment with the company's performance."It is unacceptable that Indivior's stock price has plummeted more than 50% in the past year," Andrew Diego West, a managing director at Oaktree wrote in the letter. "In the face of that value destruction, Oaktree has attempted to engage constructively with the Company's Board to address shareholder concerns and improve shareholder value. However, instead of coming to the table collaboratively and demonstrating that they are taking action, the Board and management seem to be doubling down on a failing strategy, ignoring competitive threats and allowing costs to spiral."Indivior (INDV) on Thursday responded to the Oaktree letter."The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation," Indivior said in the statement. "The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy."The Oaktree letter comes after the dual-listed U.S. drugmaker last month lowered its fiscal 2024 guidance for the second time in roughly three months, citing sales headwinds related to Sublocade, a prescription drug indicated for opioid use disorder.There's also speculation that the British biotech company may have attracted takeover interest, according to traders, who cited a Betaville "uncooked" alert that was circulating on Thursday. |
Posted at 07/11/2024 20:17 by imjustdandy Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of IndiviorSource: PR Newswire (US)RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.Indivior (PRNewsfoto/Indivior |
Posted at 21/10/2024 07:39 by tsmith2 Slough, UK, and Richmond, VA, October 15, 2024 - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will release its year-to-date and Q3 2024 results on October 24th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.Mar |
Posted at 04/9/2024 06:29 by waldron Indivior Does Not Currently Expect to Exercise AEF0117 OptionSlough, UK, and Richmond, VA, September 4, 2024 - Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma's announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD. The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD. This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option. |
Posted at 10/8/2024 05:59 by misca2 Indivior PLC Investor Notice: Robbins LLP Reminds Stockholders of the INDV Class Action LawsuitAugust 09, 2024 at 09:54 pm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Indivior PLC (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024. Indivior is a global pharmaceutical company that develops, manufactures, and markets drugs to treat opioid use disorders (“OUD”) and serious mental illnesses. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Invidior PLC (INDV) Misled Investors Regarding the Financial Prospects of its Products According to the complaint, during the class period, defendants: (i) grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than Defendants had led investors and analysts to believe; (ii) overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company’s anticipated revenue and other financial metrics; (iii) knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY2024 net revenue guidance, including FY2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; and (iv) knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS. On July 9, 2024, Indivior issued a press release "announc[ing] a business update encompassing [its] outlook for [second quarter (‘Q2’)] and FY2024 financial performance." The July 9 Update reduced FY 2024 (i) total net revenue guidance to $1.15-$1.215 billion from the previous ranges of $1.24-$1.33 billion; (ii) SUBLOCADE net revenue guidance to $765-$805 million from the previous range of $820-$880 million; and (iii) OPVEE net revenue guidance to $9-14 million from the previous range of $15-25 million. The July 9 Update also shockingly advised that the Company would immediately cease all sales and marketing activities related to PERSERIS. On this news, Indivior's stock price fell $5.15 per share, or 33.57%, to close at $10.19 per share. What Now: You may be eligible to participate in the class action against Invidior PLC. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by October 1, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Invidior PLC settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. View source version on businesswire.com: |
Posted at 05/12/2023 16:08 by waldron Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)05/12/2023 2:06pm UK Regulatory (RNS & others) Tuesday 5 December 2023 TIDMINDV RNS Number : 7595V Indivior Prevails in Striking Representative Claims from UK Shareholder Action Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant. In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser. After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here . Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings. Wirral may seek permission to appeal the Court's judgment. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/com This release is being made by Kathryn Hudson, Company Secretary Indivior PLC. Media Contacts : US Media : Cassie France-Kelly Vice President, Communications Indivior PLC Tel: 804-724-0327 UK Media : Teneo Tel: +44 207-353-4200 Investors and Analysts : Jason Thompson Vice President, Investor Relations Indivior PLC Tel: 804-402-7123 Tim Owens Director, Investor Relations Indivior PLC Tel: 804-263-3978 -ends- (END) Dow Jones Newswires December 05, 2023 09:06 ET (14:06 GMT) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
